References:
1. RC RCKK, M MPP, NA NASS, AM AMZZ, U HWWH: Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. International journal of methods in psychiatric research. 2012:169-184.
2. Yu W, Singh S, Calhoun S, Zhang H, Zhao X, Yang F: Generalized Anxiety Disorder in Urban China: Prevalence, Awareness, and Disease Burden. J Affect Disorders 2018:89.
3. Tempesta D, Mazza M, Serroni N, Moschetta FS, Berardis DD: Neuropsychological functioning in young subjects with generalized anxiety disorder with and without pharmacotherapy. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2013, 45:236-241.
4. Huang Y, Wang Y, Wang H, Liu Z, Yu X, Yan J, Yu Y, Kou C, Xu X, Lu J: Prevalence of mental disorders in China: a cross-sectional epidemiological study. The Lancet Psychiatry 2019.
5. Phillips MR, Zhang J, Shi Q, Song Z, Wang Z: Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey. Lancet 2009, 373:2041-2053.
6. Stein MB, Sareen J: Generalized Anxiety Disorder. New Engl J Med 2013, 373:2059-2068.
7. Bartlett AA, Singh R, Hunter RG: Anxiety and Epigenetics. Neuroepigenomics in Aging and Disease 2017.
8. Shen ZA, Zhu JA, Yuan YB, Ren LA, Qian MA, Lin MA, Cai MA, Zhang ZA, Shen XC: The roles of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) in predicting treatment remission in a Chinese Han population with generalized anxiety disorder - ScienceDirect. Psychiat Res 2019, 271:319-324.
9. Sharma S, Powers A, Bradley B, Ressler KJ: Gene × Environment Determinants of Stress- and Anxiety-Related Disorders. Annu Rev Psychol 2016, 67:239-261.
10. Carr CP, Martins C, Stingel AM, Lemgruber VB, Juruena MF: The role of early life stress in adult psychiatric disorders: a systematic review according to childhood trauma subtypes. Journal of Nervous & Mental Disease 2013, 201:1007-1020.
11. Michopoulos V, Powers A, Gillespie CF, Ressler KJ, Jovanovic T: Inflammation in Fear- and Anxiety-Based Disorders: PTSD, GAD and Beyond. Neuropsychopharmacology Official Publication of the American College of Neuropsychopharmacology 2016, 42:254.
12. Schwarcz, R.: Manipulation of Brain Kynurenines: Glial Targets, Neuronal Effects, and Clinical Opportunities. J.pharmacol.exp.ther 2002, 303:1-10.
13. Rothhammer V, Mascanfroni ID, Bunse L, Takenaka MC, Kenison JE, Mayo L, Chao CC, Patel B, Yan R, Blain M: Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med 2016.
14. Rothermundt M, Peters M, Prehn JH, Arolt V: S100B in brain damage and neurodegeneration. Microsc Res Tech 2010, 60:614-632.
15. Schwartz DE, Dull RO, Xu H, Changyaleket B, Zhao ZC: Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases. Curr Med Chem 2016, 23:-.
16. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE: Serum markers support disease-specific glial pathology in major depression. Journal of Afferctive Disorders 2008, 111:271-280.
17. Brown, Timothy, A., Campbell, Laura, A., Lehman, Cassandra, L., Grisham: Current and Lifetime Comorbidity of the DSM-IV Anxiety and Mood Disorders in a Large Clinical.... J Abnorm Psychol 2001, 110:585.
18. Haktan MEHS: Melatonin reverses depressive and anxiety like-behaviours induced by diabetes: involvement of oxidative stress, age, rage and S100B levels in the hippocampus and prefrontal cortex of rats. Arch Physiol Biochem 2019:1-9.
19. Kim SH, Smith CJ, Eldik L: Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production. Neurobiol Aging 2004, 25:431-439.
20. Loftis JM, Juno V, Jonathan T, Huang E, Rebekah H, Patricia TY, Chang M, Ho SB, Eric D, Luis MJ: S100B and Inflammatory Cytokine Levels in Blood as Potential Markers of Blood–Brain Barrier Damage and Psychiatric Impairment in Comorbid Hepatitis C Viral Infection and Alcohol Use Disorder. Alcoholism Clinical & Experimental Research 2018.
21. Marenholz I, Heizmann CW, Fritz G: S100 proteins in mouse and man: From evolution to function and pathology. 2004.
22. Hou R, Garner M, Holmes C, Osmond C, Teeling J, Lau L, Baldwin DS: Peripheral inflammatory cytokines and immune balance in Generalised Anxiety Disorder: Case-controlled study. Brain, Behavior, and Immunity 2017, 62:212-218.
23. Howard HCRL: Systematic review and meta-analysis of the association between peripheral inflammatory cytokines and generalised anxiety disorder. Bmj Open 2019, 9:e27925.
24. Bianchi R, Kastrisianaki E, Giambanco I, Donato R: S100B Protein Stimulates Microglia Migration via RAGE-dependent Up-regulation of Chemokine Expression and Release. J Biol Chem 2011, 286:7214-7226.
25. Gos T, Schroeter ML, Lessel W, Bernstein HG, Dobrowolny H, Schiltz K, Bogerts B, Steiner J: S100B-immunopositive astrocytes and oligodendrocytes in the hippocampus are differentially afflicted in unipolar and bipolar depression: A postmortem study. J Psychiatr Res 2013, 11:1694-1699.
26. T TGG, ML MLSS, W WLL, HG HBB, H HDD, K KSS, B BBB, J JSS: S100B-immunopositive astrocytes and oligodendrocytes in the hippocampus are differentially afflicted in unipolar and bipolar depression: a postmortem study. Journal of psychiatric research. 2013:1694-1699.
27. A ALL, E EGG, O OVV, J JPP, A AAA, L LGG: Reduced hippocampal IL-10 expression, altered monoaminergic activity and anxiety and depressive-like behavior in female mice subjected to chronic social instability stress. Behavioural brain research. 2017:8-18.
28. Tulner DM, Smith ORF, De Jonge P, Van Melle JP, Slomp J, Storm H, Quere M, Den Boer JA, Honig A, Korf J: Circulating cerebral S100B protein is associated with depressive symptoms following myocardial infarction. Neuropsychobiology 2009, 59:87-95.
29. Bergh CD, B Ckstr M M, Axelsson K, J Nsson H, Johnsson P: Protein S100B after cardiac surgery: an indicator of long-term anxiety? Scandinavian Cardiovascular Journal Scj 2007, 41:109.
30. Uher T, Bob P: Cerebrospinal fluid S100B levels reflect symptoms of depression in patients with non-inflammatory neurological disorder. Neurosci Lett 2012, 529:139-143.
31. Rahati M, Nozari M, Eslami H, Shabani M, Basiri M: Effects of enriched environment on alterations in the prefrontal cortex GFAP- and S100B-immunopositive astrocytes and behavioral deficits in MK-801-treated rats. Neuroscience 2016, 326:105-116.
32. Buschert J, Hohoff C, Touma C, Palme R, Rothermundt M, Arolt V, Zhang W, Ambrée O: S100B overexpression increases behavioral and neural plasticity in response to the social environment during adolescence. J Psychiatr Res 2013, 47:1791-1799.
33. Rong H, Wang G, Liu T, Wang H, Wan Q, Weng S: Chronic Mild Stress Induces Fluoxetine-Reversible Decreases in Hippocampal and Cerebrospinal Fluid Levels of the Neurotrophic Factor S100B and Its Specific Receptor. Int J Mol Sci 2010, 11:5310-5322.
34. Zhen T, Gang Y, Chen X, Pan M, Hou R: Peripheral proinflammatory cytokines in Chinese patients with generalised anxiety disorder. J Affect Disorders 2018, 225:593-598.
35. N NVV, AT ATFB, de Jonge De Jonge P P, BW BWJH: Anxiety disorders and inflammation in a large adult cohort. Translational psychiatry. 2013:e249.
36. Martinez P, Lien L, Zemore S, Bramness JG, Neupane SP: Circulating cytokine levels are associated with symptoms of depression and anxiety among people with alcohol and drug use disorders. J Neuroimmunol 2018:S1828043799.
37. A ALL, E EGG, O OVV, J JPP, A AAA, L LGG: Reduced hippocampal IL-10 expression, altered monoaminergic activity and anxiety and depressive-like behavior in female mice subjected to chronic social instability stress. Behavioural brain research. 2017:8-18.
38. Wen-Jun, Su, Zhi-Yong, Cao, Chun-Lei, Jiang: Blocking the trigger: An integrative view on the anti-inflammatory therapy of depression - ScienceDirect. Brain, Behavior, and Immunity 2019, 82:10-12.